Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Radioligand Therapy Market Expansion From $7.32 Billion In 2026 To $10.72 Billion In 2030
The radioligand therapy market has seen swift expansion in recent times. Its value is projected to rise from $6.63 billion in 2025 to $7.32 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.4%. Historically, this growth has been driven by factors such as the scarce supply of radioligands, a dependence on standard cancer treatments, heightened recognition of the advantages offered by targeted therapies, greater integration of nuclear medicine methods in hospitals, and regulatory clearances granted for early radioligand therapy (RLT) drugs.
The radioligand therapy market is projected to experience significant expansion over the coming years, reaching a valuation of $10.72 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.0%. This forecasted growth is fueled by the development of novel alpha and beta emitters, the expansion of combined emission therapies, deeper integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and heightened investment in home care and outpatient radioligand therapy services. Key trends shaping the period include the growing adoption of targeted radioligand therapy in oncology, the broadening of alpha and beta emitter-based treatment options, the incorporation of radioligand therapy into personalized medicine frameworks, the expansion of radioligand therapy programs within hospitals and research institutions, and an intensified focus on minimizing adverse effects while improving patient outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
Radioligand Therapy Market Expansion Supported By Key Demand Factors
The rising prevalence of cancer is anticipated to drive expansion in the radioligand therapy market in the coming years. Cancer is characterized by the unregulated proliferation of abnormal cells, which can infiltrate adjacent tissues and metastasize throughout the body. This increase in cancer cases is driven by prolonged exposure to environmental contaminants that damage DNA, impair cellular processes, and encourage irregular cell growth. Radioligand therapy addresses cancer by delivering radiation directly to tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissue and eliminating cancer cells from within. As an example, in October 2025, the National Health Service (NHS), a government health agency in the UK, reported 354,820 new cancer diagnoses in 2023—an average of 972 per day—representing an increase of 8,605 compared to 2022. Consequently, the growing incidence of cancer is fueling the advancement of the radioligand therapy market.
Radioligand Therapy Market Segments: Where Are The Largest Growth Opportunities?
The radioligand therapy market covered in this report is segmented –
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)
Radioligand Therapy Market Growth Trends Influencing Competitive Dynamics
Leading players in the radioligand therapy market are concentrating on developing innovative solutions, such as specialized radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards during the manufacturing and distribution of targeted cancer therapies. These facilities are bespoke centers engineered to manage and administer radioactive drugs for precision cancer treatment, leveraging cutting-edge imaging technologies and radiation shielding while ensuring safety via well-trained staff and rigorous procedures. For example, in January 2024, Novartis AG, a pharmaceutical company headquartered in Switzerland, unveiled the automation of its new large-scale radioligand therapy (RLT) production facility located in Indiana. This plant gained approval from the Food and Drug Administration (FDA) for commercial manufacturing. Spanning 70,000 square feet, it stands as Novartis’s largest and most advanced site dedicated to RLT, designed for efficient, time-sensitive production, and includes provisions for fully automated production lines, facilitating substantial supply increases to address rising patient demand across the United States and Canada.
Radioligand Therapy Market Major Participants And Competitive Dynamics
Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.
Access The Complete Radioligand Therapy Market Report:
Radioligand Therapy Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model